What does Enimmune corporation do?

Enimmune corporation (6564.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.

What is 6564.TWO's market cap?

Enimmune corporation (6564.TWO) has a market capitalization of approximately $1.21 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.

Does 6564.TWO pay a dividend?

No — Enimmune corporation (6564.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.

Is 6564.TWO profitable?

Enimmune corporation (6564.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.

6564.TWO

Enimmune corporation

TWO·Biotechnology · Healthcare

NT$16.80NT$0.70+4.35%

Market capNT$1.21B·Market closed·Aug 26 6:58 AM UTC

Price Chart

NT$16.80+NT$0.70 (+4.35%)today

−62.53%CAGR −17.83%

Select date range

FromTo

Sep 18, 2018Aug 26, 2021 → Aug 26, 2026· 5.0 yrsAug 26, 2026

Key Metrics

6564.TWO does not currently pay a dividend.

EarningsEarnings Tab

EPS (FWD)—

P/E Ratio (FWD)—

EPS Growth (1Y)—

EPS Growth (3Y)—

EPS Growth (5Y)—

Next Earnings Date—

Last Report Date—

Reported vs Estimate—

Earnings Surprise—

FinancialsFinancials Tab

RevenueNT$53.45M

Net Income−NT$120.88M

Net Margin−226.2%

Operating Cash Flow−NT$83.45M

Capital ExpendituresNT$2.75M

Free Cash Flow−NT$86.19M

Return on Equity−120.4%

Return on Invested Capital−18.8%

Net CashNT$33.88M

Value Graph

PRO

See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.

Click below to see what's inside, then upgrade to unlock for 6564.TWO and 80,000+ other tickers.

EPS · Price vs. Fair Value Price Fair

Income Statement Flow

PRO

See exactly how 6564.TWO's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.

The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for 6564.TWO and 80,000+ other tickers.

About Enimmune corporation

Enimmune Corporation is a Taiwanese biopharmaceutical company primarily focused on the research, development, and commercialization of pharmaceutical products. Among its key offerings is Tuberculin PPD RT23 SSI, an approved diagnostic agent utilized in tuberculin tests to ascertain the presence of tuberculosis infection in patients. Beyond its existing products, Enimmune is heavily invested in developing vaccines aimed at combating a diverse array of infectious diseases. These include, but are not limited to, vaccines for enterovirus, pneumonia, norovirus, dengue fever, and Middle East…

CEO: Zhe Wei Zhang
Sector: Healthcare
Industry: Biotechnology
Exchange: TWO
Employees: 27
Website: www.enimmune.com.tw

Peers

GeneReach Biotechnology Corp.

Cap

NT$994.2M

7427.TWO

Great Novel Therapeutics Biotech & Medicals

Cap

NT$4.0B

Latest News

News Tab

No recent news available.

Frequently Asked Questions About 6564.TWO

What does Enimmune corporation do?: Enimmune corporation (6564.TWO) operates in the Biotechnology industry within the Healthcare sector. Full company description, peers, and segment breakdown are on the page above.
What is 6564.TWO's market cap?: Enimmune corporation (6564.TWO) has a market capitalization of approximately $1.21 billion, as of August 26, 2026, based on the most recent share price and shares outstanding.
Does 6564.TWO pay a dividend?: No — Enimmune corporation (6564.TWO) does not currently pay a regular dividend. Many growth-stage companies reinvest earnings into the business instead of returning capital to shareholders. The Dividend tab tracks any future declarations.
Is 6564.TWO profitable?: Enimmune corporation (6564.TWO) currently reports negative earnings on a trailing-twelve-month basis. The Earnings and Financials tabs show the full EPS history, revenue trend, and analyst forecasts for future profitability.